X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AG-881 (vorasidenib) is an oral, selective, highly brain-penetrant dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes. It is being evaluated for the treatment of IDH-mutant diffuse glioma.
Lead Product(s): Vorasidenib
Therapeutic Area: Oncology Product Name: AG-881
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
The agreement aims to develop RNA-targeted small molecule therapeutics by leveraging Base4's pioneering drug discovery platform to identify RNA-modulating small molecules to enable and accelerate Servier's research in neuroscience drug candidates.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Recipient: Base4 Biotechnology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 05, 2024
Details:
AG-881 (vorasidenib) is an oral, brain-penetrant, dual inhibitor of mutant (m)IDH1/2 enzymes. It is being evaluated for the treatment of IDH-Mutant Diffuse Glioma.
Lead Product(s): Vorasidenib
Therapeutic Area: Oncology Product Name: AG-881
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2023
Details:
Tibsovo (ivosidenib) tablet is a small molecule inhibitor that targets the mutant isocitrate dehydrogenase 1 enzyme, which is investigated for IDH1-mutated Relapsed or refractory myelodysplastic syndromes.
Lead Product(s): Ivosidenib
Therapeutic Area: Oncology Product Name: Tibsovo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Details:
TIBSOVO® (ivosidenib) tablet is a small molecule inhibitor that targets the mutant isocitrate dehydrogenase 1 enzyme, which is investigated for IDH1-mutated Relapsed or refractory myelodysplastic syndromes.
Lead Product(s): Ivosidenib
Therapeutic Area: Oncology Product Name: Tibsovo
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2023
Details:
Aitia and Servier will focus to discover, validate, and strive to develop novel drug targets and candidates in pancreatic cancer by utilizating Aitia's Pancreatic Cancer Digital Twins and Servier's pre-clinical assays, therapeutic creation platforms, and expertise.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Aitia
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 17, 2023
Details:
Tibsovo® (ivosidenib tablets) is the first and only IDH1 inhibitor approved in Europe. It has received orphan medicine designation recognizing the significant benefit brought to patients by Tibsovo® over available therapies for both CCA and AML.
Lead Product(s): Ivosidenib
Therapeutic Area: Oncology Product Name: Tibsovo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2023
Details:
AG-881 (vorasidenib) is a first-in-class, brain-penetrant, dual inhibitor of the mutant IDH1 and mutant IDH2 enzymes. It is beinf developed for the treament of IDH-mutant low-grade glioma.
Lead Product(s): Vorasidenib
Therapeutic Area: Oncology Product Name: AG-881
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
Tibsovo (ivosidenib) is a small molecule inhibitor that targets the mutant isocitrate dehydrogenase 1 (IDH1) enzyme. In patients with AML, susceptible IDH1 mutations are defined as those leading to increased levels of 2-hydroxyglutarate (2-HG) in the leukemia cells.
Lead Product(s): Ivosidenib
Therapeutic Area: Oncology Product Name: Tibsovo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2023
Details:
Lonsurf is an oral nucleoside antitumor agent which consists trifluridine, and tipiracil (TP inhibitor), which increases trifluridine exposure by inhibiting its metabolism by TP. Trifluridine results in DNA dysfunction and inhibition of cell proliferation.
Lead Product(s): Trifluridine,Tipiracil Hydrochloride,Bevacizumab
Therapeutic Area: Oncology Product Name: Lonsurf
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Taiho Oncology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
